FL-NEURON
9.4.2024 14:01:32 CEST | Business Wire | Press release
Neuron, a QoE management platform for things that move, announced today that it’s making its network APIs available to maritime solution providers and app developers to enable application-driven quality of experience (QoE) on demand. With Neuron’s network APIs, cruise, shipping, energy and more can reimagine connectivity and QoE for critical onboard services such as medical, disaster response, remote monitoring and management and more, resulting in higher standards of safety and well-being for passengers and crew.
As part of today’s announcement, Neuron, VIKAND, a global leader in maritime healthcare, and FrontM, creator of a low code software platform for maritime, have unveiled a partnership to explore a variety of ways to transform onboard medical services across the maritime industry.
Bandwidth Orchestration in Maritime is Highly Manual and Inefficient
During emergency situations at sea, the apps and services supporting response efforts need exponentially more bandwidth, with elevated QoE, to accelerate response times, communication and decision-making. Consider an already busy network with passengers, crew and corporate teams using the majority of available data capacity, and then add to the mix a medical team managing an emergency on the ship – they might need more than 100 Mbps of symmetrical bandwidth on demand to transfer large files, conduct an HD video conference with remote specialists, perform telediagnosis and more.
Today, it’s not possible to dynamically orchestrate bandwidth across multiple providers and update QoS and network configurations for short periods of time, while also ensuring a high-quality end-user experience – without disrupting all other activity on the ship. Instead, cruise teams have to manually configure and provision capacity to manage this type of request, and prioritize and allocate the bandwidth to the application accordingly. This process is clunky, expensive and can often take days, leaving onboard solution teams to resort to workarounds that are less efficient.
Neuron Network APIs Enable Multi-Provider, AI-Powered Connectivity Orchestration
With Neuron’s network APIs, maritime solution providers and app developers can connect their apps directly to Neuron’s AI-powered network management solution, Neuron Grid, to programmatically request QoE on demand. When an app triggers a request, Neuron will use AI and machine learning to orchestrate network changes and deliver the capacity the app needs, in real-time, with the most optimal QoE – all the onboard team needs to do is press a button in an app. Unlike other network management solutions, Neuron can seamlessly blend any combination of connectivity – whether single- or multi-provider, -orbit or -network – in one, vendor-neutral environment.
“Telecom network APIs are incredibly powerful, but they’ve always been focused on cellular, limiting their value for maritime companies that rely on LTE, satellite and Wi-Fi,” said Benny Retnamony, founder and CEO, Neuron. “Because Neuron enables multi-provider access with AI-powered network management, we are uniquely positioned to facilitate application-driven QoE on demand for the maritime industry. We look forward to collaborating with a range of maritime solution providers to unlock the next generation of apps and services at sea.”
Neuron, VIKAND and FrontM Partner to Transform Onboard Medical Services
Neuron, VIKAND and FrontM are collaborating to explore a variety of ways to use Neuron’s QoE management platform to rethink both emergency and non-emergency medical services for maritime. With Neuron’s network APIs, VIKAND can ensure continuity of care, especially in the event of an emergency when reliable, high-quality connectivity is critical. This will make it possible for doctors to use modern digital imaging equipment for high-resolution X-rays and ultrasounds, or more advanced medical equipment, like smart stethoscopes, right from the ship.
- “On-demand, agile and elastic connectivity is needed to enable advanced healthcare technologies and solutions at sea,” added Benny Retnamony, founder and CEO of Neuron. “Through our partnership with VIKAND and FrontM, we are committed to demonstrating how application-driven QoE on demand orchestrated through the Neuron platform can clear the way for VIKAND to accelerate access to critical onboard medical services.”
- “Technology and connectivity are critical to any vessels at sea,” says Ronald Spithout, Managing Director of OneHealth by VIKAND. “VIKAND together with FrontM are always striving to deploy state of the art modern technology to improve healthcare possibilities at sea. In this context, the integration with Neuron's quality of experience management platform opens the possibility to automatically link available capacity that best matches the specific application requirement of that very moment, which could make all the difference when talking healthcare and/or medical emergencies. VIKAND is delighted to be partnering with Neuron to deploy this technology to the benefit of improving welfare at sea, where it adds value to our operations, preserves crew value and benefits the maritime industry as a whole.”
- Guillermo Acilu, CTO, FrontM adds, “We are excited to harness enhanced connectivity by combining Neuron’s network management API and FrontM’s low-code frameworks for Vikand’s healthcare solution. This is groundbreaking for not only Vikand’s doctors and the crew to access advanced solutions with dynamically elevated connectivity but also to bring efficiency and assurance to the customer at the same time. This partnership with Neuron opens up significant opportunities to maximise the customer experience for a vast array of applications in our app marketplace.”
Click here to view a short demo video by Neuron, VIKAND and FrontM.
Unlocking the Next Generation of Apps and Services at Sea
Application-driven QoE on demand for critical onboard services is just the beginning. In the future, maritime solution providers can also use Neuron’s network APIs to unlock differentiated and personalized passenger experiences. For example, tailoring IPTV content and quality for special events, like Sunday Night Football; dynamic content caching prepositioning for high-definition VoD; or throwing hyper-connected live events and festivals in the middle of the ocean.
Neuron is committed to working with additional partners to explore new ways to use its network APIs for a diverse range of use cases.
About Neuron
Neuron is the first AI-powered QoE management platform for things that move. It uses AI and machine learning to seamlessly blend any combination of connectivity, regardless of provider, orbit or network, in one, vendor-neutral environment, enabling comprehensive analytics and dynamic network orchestration that optimizes for the best possible quality of experience (QoE) – even in the most remote and hard-to-reach places.
Today, Neuron works with world-leading, Fortune 500 companies in aviation, cruise, shipping and more. To learn more, visit: www.getneuron.com and follow us on LinkedIn.
About VIKAND
VIKAND is a leading expert in global medical services and risk mitigation solutions for the maritime industry, operating a global network of 1,500 maritime medical professionals, established across 44 countries, supported by 4 main locations. VIKAND’s caring and committed teams manage more than 4,100 daily maritime medical encounters.
With OneHealth, VIKAND offers a preventive maintenance approach to optimizing the physical and mental health of seafarers. A ship at sea is a standalone ecosystem where people live and work interdependently. OneHealth takes a diversified and inclusive approach to protecting the health and wellness of all onboard.
VIKAND all-inclusive approach unifies preparedness, prevention, detection, response, and management across a range of healthcare concerns, from communicable diseases to chronic illnesses, mental health concerns and more. www.vikand.com
About FrontM
FrontM is a UK Headquartered, collaboration software company offering a comprehensive superapp platform for the maritime industry. By connecting service providers, solution providers, ship operators and their crews, FrontM facilitates improved communications, collaboration, crew welfare and operational efficiency at sea.
Delivering a unique suite of marketplace apps for companies to prioritise crew connectivity and operate the ship as an extension of the shore ranging from crew healthcare enabling medical specialists to deliver comprehensive care, to crew training and skills development with social and just-in-time learning tools, crew entertainment with the industry’s first live IP-TV, together with crew social internet, video conferencing and virtual events.
With a focus on digitalisation and a one-stop solution for integrating services, FrontM is dedicated to overcoming the challenges of app fatigue and advancing the maritime industry's digital transformation. www.frontm.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240409591486/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom